Urogenital transitional cell carcinoma in dogs: piroxicam + mitoxantrone vs piroxicam + carboplatin — POSSIBLE

In dogs with urogenital transitional cell carcinoma, which first-line combination with piroxicam — mitoxantrone or carboplatin — gives longer progression-free interval and survival?

Shelf #115 · gate-verified and approved by the developer

POSSIBLE: Neither combination won. In the one randomised phase III trial (50 dogs, open-label), progression-free interval was 106 days on mitoxantrone + piroxicam versus 73.5 days on carboplatin + piroxicam — a numerical gap that was not significant (P = .62; hazard ratio 0.86, 95% CI 0.47-1.56), so on this evidence the choice of cytotoxic partner made no demonstrated difference (the treatment made no difference). Responses were uncommon and never complete: partial responses in 8% (mitoxantrone) versus 13% (carboplatin), with stable disease in 69% versus 54%. Tier C (survival-family claim). What did predict survival was tumour site: dogs with prostatic involvement lived a median of 109 days versus 300 (urethral), 190 (trigonal) and 645 days (apical). The trial was open-label — blinding is not established — and at 50 dogs it cannot exclude a moderate true difference in either direction. Drafted Nov 10, 2026 (VetMed build, topic #115); all figures from abstracts fetched and verified at drafting.

Allstadt 2015: mitoxantrone vs carboplatin, both with piroxicam — PFI 106 vs 73.5 days, not significant (P = .62)

Randomized phase III trial (record's own title wording; abstract: 'Prospective open-label phase III randomized study')

Who: Dogs: 50 dogs with urogenital tract transitional cell carcinoma (TCC) without azotemia, in a prospective open-label phase III randomised study — 26 dogs received mitoxantrone and 24 received carboplatin, each administered every 3 weeks concurrently with piroxicam, with restaging at 6-week intervals.

Result: Response was not different between groups (P = .56). None of the dogs showed complete response. In the mitoxantrone group there were 2 (8%) partial responses (PR) and 18 (69%) dogs with stable disease (SD); in the carboplatin group, 3 PR (13%) and 13 (54%) dogs with SD. The progression-free interval was not significantly different between groups (mitoxantrone = 106 days; carboplatin = 73.5 days; P = .62; hazard ratio 0.86; 95% confidence interval 0.47-1.56) (the treatment made no difference). Dogs with prostatic involvement experienced a shorter survival (median, 109 days) compared to dogs with urethral, trigonal, or apically located tumors (median 300, 190, and 645 days, respectively; P = .005).

Watch out: Open-label by the record's own wording: randomisation is established, blinding is not — clinicians and assessors knew the treatment, which can bias restaging and progression calls. The hazard-ratio confidence interval (0.47-1.56) is wide: a moderate benefit for either drug remains compatible with these data, so this is 'no difference detected', not equivalence proven. Dogs with azotemia were excluded, so the result does not cover TCC dogs with renal compromise.

Allstadt SD, Rodriguez CO, Boostrom B, Rebhun RB, Skorupski KA. Randomized phase III trial of piroxicam in combination with mitoxantrone or carboplatin for first-line treatment of urogenital tract transitional cell carcinoma in dogs. J Vet Intern Med. 2015;29(1):261-7. PMID: 25619518. Registry ID: none in the record. MeSH: Animals · Dogs · Female · Male · Antineoplastic Agents · Carboplatin · Carcinoma, Transitional Cell · Dog Diseases · Drug Therapy, Combination · Mitoxantrone · Piroxicam · Urogenital Neoplasms

Synthesis: one open-label randomised trial — pick on toxicity and practicality, not on expected control time

Synthesis

Who: Synthesis of the card above: Allstadt 2015 (prospective open-label phase III randomised study; 26 mitoxantrone + piroxicam vs 24 carboplatin + piroxicam dogs with urogenital TCC without azotemia).

Result: The head-to-head randomised comparison found no significant difference in response or progression-free interval between mitoxantrone + piroxicam and carboplatin + piroxicam (the treatment made no difference), and no dog in either arm achieved a complete response. Prognosis in this trial tracked anatomy, not drug choice: prostatic involvement carried a median survival of 109 days against 645 days for apical tumours. Until a larger or blinded trial says otherwise, the partner drug should be chosen on the individual dog's organ function, toxicity profile and logistics rather than on an expectation of longer control.

Watch out: Single trial, 50 dogs, open-label. The older non-randomised single-arm literature (e.g. mitoxantrone + piroxicam case series) reported higher response rates, but without a randomised comparator those numbers cannot rank the two combinations and are not carded as evidence here.

Synthesis of Allstadt SD et al. PMID: 25619518. Registry ID as on the individual card.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.